<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Ma J</submitter><funding>NHLBI NIH HHS</funding><funding>NIAAA NIH HHS</funding><pagination>19564</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9664436</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>12(1)</volume><pubmed_abstract>DNA methylation commonly occurs at cytosine-phosphate-guanine sites (CpGs) that can serve as biomarkers for many diseases. We analyzed whole genome sequencing data to identify DNA methylation quantitative trait loci (mQTLs) in 4126 Framingham Heart Study participants. Our mQTL mapping identified 94,362,817 cis-mQTLvariant-CpG pairs (for 210,156 unique autosomal CpGs) at P &lt; 1e-7 and 33,572,145 trans-mQTL variant-CpG pairs (for 213,606 unique autosomal CpGs) at P &lt; 1e-14. Using cis-mQTL variants for 1258 CpGs associated with seven cardiovascular disease (CVD) risk factors, we found 104 unique CpGs that colocalized with at least one CVD trait. For example, cg11554650 (PPP1R18) colocalized with type 2 diabetes, and was driven by a single nucleotide polymorphism (rs2516396). We performed Mende</pubmed_abstract><journal>Scientific reports</journal><pubmed_title>Elucidating the genetic architecture of DNA methylation to identify promising molecular mechanisms of disease.</pubmed_title><pmcid>PMC9664436</pmcid><funding_grant_id>U01 HL120393</funding_grant_id><funding_grant_id>R01 HL120393</funding_grant_id><funding_grant_id>75N92019D00031</funding_grant_id><funding_grant_id>HHSN268201000021C</funding_grant_id><funding_grant_id>K22 HL135075</funding_grant_id><funding_grant_id>R01 HL155569</funding_grant_id><funding_grant_id>HHSN268201500001I</funding_grant_id><funding_grant_id>N01HC25195</funding_grant_id><funding_grant_id>HHSN268201000001I</funding_grant_id><funding_grant_id>R01 AA028263</funding_grant_id><pubmed_authors>Heard-Costa NL</pubmed_authors><pubmed_authors>Vasan RS</pubmed_authors><pubmed_authors>Bui H</pubmed_authors><pubmed_authors>Sooda M</pubmed_authors><pubmed_authors>Courchesne P</pubmed_authors><pubmed_authors>Keshawarz A</pubmed_authors><pubmed_authors>Pitsillides AN</pubmed_authors><pubmed_authors>Hwang SJ</pubmed_authors><pubmed_authors>Sharopova N</pubmed_authors><pubmed_authors>Huan T</pubmed_authors><pubmed_authors>Munson PJ</pubmed_authors><pubmed_authors>Levy D</pubmed_authors><pubmed_authors>Tejada B</pubmed_authors><pubmed_authors>Ma J</pubmed_authors><pubmed_authors>Demirkale CY</pubmed_authors><pubmed_authors>Liu C</pubmed_authors><pubmed_authors>Joehanes R</pubmed_authors><pubmed_authors>Feolo M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Elucidating the genetic architecture of DNA methylation to identify promising molecular mechanisms of disease.</name><description>DNA methylation commonly occurs at cytosine-phosphate-guanine sites (CpGs) that can serve as biomarkers for many diseases. We analyzed whole genome sequencing data to identify DNA methylation quantitative trait loci (mQTLs) in 4126 Framingham Heart Study participants. Our mQTL mapping identified 94,362,817 cis-mQTLvariant-CpG pairs (for 210,156 unique autosomal CpGs) at P &lt; 1e-7 and 33,572,145 trans-mQTL variant-CpG pairs (for 213,606 unique autosomal CpGs) at P &lt; 1e-14. Using cis-mQTL variants for 1258 CpGs associated with seven cardiovascular disease (CVD) risk factors, we found 104 unique CpGs that colocalized with at least one CVD trait. For example, cg11554650 (PPP1R18) colocalized with type 2 diabetes, and was driven by a single nucleotide polymorphism (rs2516396). We performed Mende</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Nov</publication><modification>2026-04-08T18:20:36.333Z</modification><creation>2025-02-19T01:28:39.898Z</creation></dates><accession>S-EPMC9664436</accession><cross_references><pubmed>36380121</pubmed><doi>10.1038/s41598-022-24100-0</doi></cross_references></HashMap>